Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid TumorsJohanna C. Bendell, José Baselga|Journal of Clinical Oncology|2011Cited by 684
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Karl D. Lewis et al.|The Lancet Oncology|2012Cited by 541
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Yoon‐Koo Kang et al.|The Lancet Oncology|2020Cited by 190
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitorJohanna C. Bendell, Amita Patnaik|British Journal of Cancer|2017Cited by 132
Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient TreatmentValentina Nardi, Dora Dias‐Santagata, Peter M. Sadow et al.|Clinical Cancer Research|2012Cited by 112